Bivalent RSV prefusion F protein–based vaccine for preventing cardiovascular hospitalizations in older adults

JAMA

2025-08-30

(Press-News.org) About The Study: In adults age 60 or older, all-cause cardiorespiratory hospitalization was significantly lower with respiratory syncytial virus (RSV) prefusion F protein than with no vaccine. The findings suggest potential downstream cardiorespiratory benefits of RSV immunization, although the effect on all-cause cardiovascular hospitalization was not statistically significant.

Corresponding Author: To contact the corresponding author, Tor Biering-Sørensen, MD, MSc, MPH, PhD, email tor.biering@gmail.com.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.15405?guestAccessKey=c6db40fb-eda4-4735-b83a-ee7345ff263d&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=083025

END

ELSE PRESS RELEASES FROM THIS DATE:

Clonal hematopoiesis and risk of new-onset myocarditis and pericarditis

2025-08-30

About The Study: In this study, clonal hematopoiesis of indeterminate potential (CHIP) was a strong risk factor for myocarditis and pericarditis among middle-aged adults. Targeting CHIP and its downstream pathways may represent a strategy for preventing or treating pericarditis and myocarditis. Corresponding Author: To contact the corresponding author, Michael C. Honigberg, MD, MPP, email mhonigberg@mgh.harvard.edu. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ Editor’s Note: Please see the article for additional information, including other authors, author contributions ...

Risk of myocarditis or pericarditis with high-dose vs standard-dose influenza vaccine

2025-08-30

About The Study: In this prespecified analysis of the DANFLU-2 trial, the risk of incident myocarditis or pericarditis was lower among individuals randomized to high-dose inactivated influenza vaccine vs standard-dose- inactivated influenza vaccine. Despite sporadic reports of myocarditis and pericarditis associated with influenza vaccination, the consistency of our results with vs without inclusion of events occurring immediately after vaccination negates a dose-response association and a causal link. Corresponding Author: To ...

High-dose vs standard-dose influenza vaccine and cardiovascular outcomes in older adults

2025-08-30

About The Study: This study found reduced incidence of cardiorespiratory hospitalization among those who received high-dose inactivated influenza vaccine vs standard-dose inactivated influenza vaccine, driven by a lower incidence of cardiovascular hospitalizations, and particularly heart failure hospitalizations. These differences should be interpreted as exploratory findings in the setting of a large randomized clinical trial with a neutral primary outcome. Corresponding Author: To contact the corresponding author, Tor Biering-Sørensen, ...

Prevalence, determinants, and time trends of cardiovascular health in the WHO African region

2025-08-30

About The Study: This situational analysis of cross-sectional WHO STEPS surveys of cardiovascular health (CVH) status region identified actionable factors of the CVH status across 22 countries in the WHO African Region. This information is crucial for guiding policy efforts in cardiovascular disease prevention in countries of the WHO African Region. Corresponding Author: To contact the corresponding author, Jean-Philippe Empana, MD, PhD, email jean-philippe.empana@inserm.fr. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ Editor’s Note: Please see the article for additional information, including ...

New study finds that, after a heart attack, women have worse prognosis when treated with beta-blockers

2025-08-30

A major new analysis from REBOOT (Treatment with Beta-blockers after Myocardial Infarction without Reduced Ejection Fraction) clinical trial, an international study coordinated by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), published at the European Heart Journal has revealed important sex-specific differences in the effects of beta-blockers following heart attacks, raising questions about long-standing treatment practices. REBOOT, presented in a Hotline session of the ESC congress in Madrid, ...

CNIC-led REBOOT clinical trial challenges 40-year-old standard of care for heart attack patients

2025-08-30

Madrid, August 30, 2025. An international clinical trial coordinated by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), in collaboration with the Mario Negri Institute for Pharmacological Research in Milan, has found that beta-blockers—drugs commonly prescribed for a range of cardiac conditions—offer no clinical benefit for patients who have had an uncomplicated myocardial infarction (i.e., without deterioration of the heart function after the event). The findings—published in two articles in The New England Journal of Medicine and The Lancet and presented today during a “Hot Line” ...

Systolic blood pressure and microaxial flow pump–associated survival in infarct-related cardiogenic shock

2025-08-30

About The Study: Randomization systolic blood pressure (SBP) was associated with the survival benefit of microaxial flow pump treatment, with the most hypotensive patients deriving the largest survival benefit. Early SBP may help identify patients most likely to gain a net benefit from microaxial flow pump treatment. Findings are hypothesis generating. Corresponding Author: To contact the corresponding author, Astrid Duus Mikkelsen, MD, email astrid.duus.mikkelsen@reigonh.dk. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ Editor’s Note: Please see the article for additional information, including ...

Beta blockers, the standard treatment after a heart attack, may offer no benefit for heart attack patients and women can have worse outcomes

2025-08-30

Beta blockers—drugs commonly prescribed for a range of cardiac conditions, including heart attacks—provide no clinical benefit for patients who have had an uncomplicated myocardial infarction with preserved heart function. Beta blockers have been the standard treatment for these patients for 40 years. This is a breakthrough discovery from the “REBOOT Trial” with senior investigator Valentin Fuster, MD, PhD, President of Mount Sinai Fuster Heart Hospital and General Director of Spain’s Centro Nacional de Investigaciones Cardiovasculares ...

High Mountain Asia’s shrinking glaciers linked to monsoon changes

2025-08-29

Glaciers across High Mountain Asia are losing more than 22 gigatons of ice per year—the equivalent to nearly 9 million Olympic swimming pools, according to research from the University of Utah and Virginia Tech. The impact of a warming climate on glacial loss is undisputed—this new study provides the first evidence that seasonal shifts in rainfall and snowfall patterns, particularly of the South Asian monsoons, are also exacerbating glacier melting across the region. “These findings highlight that glaciers dominated by the South Asian monsoons, such as the Central Himalaya, ...

All DRII-ed up: How do plants recover after drought?

2025-08-29

LA JOLLA (August 29, 2025)—A plant’s number one priority is to grow—a feat that demands sunlight, nutrients, and water. If just one of these three inputs is missing, like water in a drought, growth halts. You might then think that at the end of that drought, the plant would jump right back into growing. Instead, its priorities shift. Salk plant biologists used advanced single-cell and spatial transcriptomic techniques to look closely at how a small, flowering plant called Arabidopsis thaliana recovers after drought. They discovered that immunity became the plant’s number one priority during this ...

Bivalent RSV prefusion F protein–based vaccine for preventing cardiovascular hospitalizations in older adults

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: